Research programme: anticancer monoclonal antibodies - A&G Pharmaceutical
Alternative Names: Anti-GP88 monoclonal antibody; Anti-PCDGF monoclonal antibody; Anti-PCDGF-GP88 monoclonal antibody; Anti-PCDGF/GP88 monoclonal antibody; Anti-progranulin monoclonal antibody; CT P4; PC-cell-derived growth factor - A&G PharmaceuticalLatest Information Update: 28 Mar 2018
At a glance
- Originator A&G Pharmaceutical
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Intercellular signalling peptide and protein inhibitors; PC cell-derived growth factor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Lung cancer
Most Recent Events
- 28 Mar 2018 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral)
- 28 Mar 2018 No recent reports of development identified for preclinical development in Lung-cancer in USA (Parenteral)
- 16 Mar 2016 Preclinical development is ongoing for Breast cancer and Lung cancer in the US (Celltrion pipeline, March 2016)